
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    ### **Step-by-Step Analysis of the Marker List for Large Intestine scRNA-seq Dataset** --- #### **1. List the Key Functional Markers** The top markers are dominated by **immunoglobulin (Ig) genes** and **B-cell-related genes**, indicating a strong association with **B-cell lineage and antibody production**: - **Immunoglobulin Light Chains (IGLL5, IGLV6-57, IGLC3, IGLC2, IGKV4-1, IGKV1-5, IGLV3-1, IGLV2-11, IGKV3-20)** - Essential for antibody diversity and antigen binding. - **Immunoglobulin Heavy Chains (IGHV3-7, IGHG1, IGHV3-23, IGHG3, IGHV3-74, IGHM, IGHA1, IGHA2)** - Key for antibody class switching (IgM, IgG, IgA). - **JCHAIN, MZB1, DERL3, TNFRSF17 (BCMA)** - **JCHAIN**: Critical for IgA/IgM polymerization in mucosal immunity. - **MZB1**: A plasma cell-specific chaperone for Ig secretion. - **DERL3**: ER-associated degradation in plasma cells. - **TNFRSF17 (BCMA)**: Receptor for BAFF, critical for plasma cell survival. - **FCRL5, GPRC5D, LILRB4** - **FCRL5**: Expressed in memory B cells and plasma cells. - **GPRC5D**: Associated with plasma cells in multiple myeloma. - **LILRB4**: Immunoregulatory receptor in plasma cells. **Functional Inference**: This cluster is strongly associated with **antibody-secreting cells (ASCs)**, likely **plasma cells**, given the high expression of Ig genes, JCHAIN, and MZB1. --- #### **2. List the Key Cell Type Markers** The markers align with **B-cell lineage differentiation**, particularly **late-stage B cells (plasma cells)**: - **Plasma Cell Markers**: - **JCHAIN, MZB1, DERL3, TNFRSF17, IGLL5, IGLC2/3, IGHG1/3, IGHA1/2** - These are definitive markers of **mature plasma cells**, especially **IgA-secreting plasma cells** (dominant in mucosal tissues like the gut). - **Memory B-cell Markers (if present)**: - **FCRL5, LILRB4** (but weaker than plasma cell markers). - **Non-B-cell Contaminants?** - **MYL2, BMP6, CCL3** are not typical B-cell markers and may indicate minor contamination or rare subpopulations. **Cell Type Inference**: The dominant signature is **plasma cells**, with possible minor subsets of memory B cells. --- #### **3. Cross-reference Known Databases** - **Human Cell Atlas (HCA) / Tabula Sapiens**: - Plasma cells in the gut express **JCHAIN, IGHA1/2, MZB1, DERL3**. - **IgA plasma cells** dominate in mucosal tissues. - **ImmGen / B-cell Atlas**: - **MZB1+ DERL3+** = terminally differentiated plasma cells. - **TNFRSF17 (BCMA)** = plasma cell survival marker. - **Literature (e.g., Gut Mucosal Immunity)**: - **IgA+ plasma cells** are the major antibody-secreting population in the intestine. **Conclusion**: The markers match **gut-resident plasma cells**. --- #### **4. Determine the Most Probable General Cell Type** **General Cell Type**: **Plasma Cell (Antibody-Secreting Cell, ASC)** - Supported by: - High Ig gene expression (IgA/IgG heavy and light chains). - Plasma cell-specific markers (JCHAIN, MZB1, DERL3, TNFRSF17). --- #### **5. Identify the Top 3 Most Probable Sub Cell Types** Ranked by likelihood: 1. **IgA+ Plasma Cell (Mucosal Plasma Cell)** - **Key Markers**: IGHA1/2, JCHAIN, IGLV/IGLC, MZB1. - **Rationale**: Dominant in gut mucosa, secretes polymeric IgA for mucosal immunity. 2. **IgG+ Plasma Cell** - **Key Markers**: IGHG1/3, IGKC, FCRL5. - **Rationale**: Less common in gut but present; may derive from systemic immune responses. 3. **Memory B-cell (Minor Population)** - **Key Markers**: FCRL5, LILRB4. - **Rationale**: Weak expression suggests a small subset, but plasma cell markers dominate. **Final Subtype Call**: **IgA+ Plasma Cell** (most consistent with gut mucosal immunity). --- #### **6. Concise Summary of Analysis** - **Key Functional Markers**: Immunoglobulin genes (IgA/IgG), plasma cell-specific genes (JCHAIN, MZB1, DERL3). - **Key Cell Type Markers**: Definitive plasma cell signature (IgA-dominated). - **Database/Literature Support**: Matches gut-resident IgA+ plasma cells. - **General Cell Type**: Plasma cell (antibody-secreting). - **Top 3 Subtypes**: 1. **IgA+ Plasma Cell** (most likely). 2. IgG+ Plasma Cell. 3. Minor memory B-cell subset. **FINAL ANNOTATION COMPLETED**: **IgA+ Plasma Cell (Mucosal Plasma Cell)**. --- **Validation Note**: If further validation is needed, check for CD138 (SDC1) and CD38 (classic plasma cell markers) in the dataset, though their absence does not rule out plasma cells given the strong IgA/JCHAIN signature.
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    Validation result: VALIDATION PASSED ### **Feedback & Justification:** 1. **Marker Consistency**: - The proposed annotation (**IgA+ Plasma Cell**) is strongly supported by the provided marker list. - **Key plasma cell markers** (IGLL5, JCHAIN, IGLC3, IGLC2, IGHG1, IGHA1, MZB1, DERL3, TNFRSF17) are present and highly ranked. - **IgA-specific markers** (IGHA1, IGHA2, JCHAIN) confirm mucosal plasma cell identity. - **Immunoglobulin genes** (IGLV, IGKC, IGHG, IGHM) align with antibody-secreting function. 2. **No Evidence of Mixed Populations**: - While minor non-B-cell markers (e.g., MYL2, BMP6, CCL3) appear, they are low-ranking and likely reflect background noise or rare contaminants. - No strong conflicting markers suggest contamination by other cell types. 3. **Database/Literature Alignment**: - The signature matches gut-resident **IgA+ plasma cells** (JCHAIN+ IGHA1/2+ MZB1+), as documented in the Human Cell Atlas and mucosal immunity studies. 4. **Suggested Verification (Optional)**: - If available, check for **CD138 (SDC1)** and **CD38** to further confirm plasma cell identity, though their absence does not invalidate the annotation given the robust IgA signature. **Conclusion**: The annotation is biologically sound and well-supported by the data. Proceed with confidence.
                </div>
            
                    <div class="agent-section formatting">
                        <h2>üìã Summary</h2>
                        <p class="error-message">Error formatting data: Expecting property name enclosed in double quotes: line 1 column 3 (char 2)</p>
                    </div>
                
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">95</div>
                        <div class="scoring-content">
                            The annotation results for this single-cell dataset from the human large intestine are highly accurate and well-supported by the provided marker list. Here‚Äôs a detailed evaluation:<br><br>### **Strengths:**<br>1. **Correctness of Annotations**:<br>   - The annotation as **IgA+ Plasma Cell (Mucosal Plasma Cell)** is scientifically sound. The markers overwhelmingly support this conclusion, with strong representation of immunoglobulin genes (e.g., IGHA1/2, IGLC2/3, IGHG1/3) and plasma cell-specific markers (JCHAIN, MZB1, DERL3, TNFRSF17). These are definitive for gut-resident IgA-secreting plasma cells, as confirmed by databases like the Human Cell Atlas and literature on mucosal immunity.<br>   - The inclusion of **subtypes (IgG+ Plasma Cell, Memory B-cell)** as minor populations demonstrates nuanced understanding, even though the dominant population is clearly IgA+ plasma cells.<br><br>2. **Balanced Use of Markers**:<br>   - The analysis does not over-rely on a single marker but considers a broad spectrum of immunoglobulin genes (heavy and light chains), plasma cell-specific chaperones (MZB1), and mucosal immunity markers (JCHAIN). This holistic approach strengthens the annotation‚Äôs reliability.<br>   - The rank of markers is appropriately considered, with top-ranked markers (e.g., IGLL5, JCHAIN, IGLC3) given more weight in the final call.<br><br>3. **Comprehensive View of Cell Types**:<br>   - The annotation captures the general picture of the data well, identifying the major population (IgA+ plasma cells) while acknowledging potential minor subsets (IgG+ plasma cells, memory B-cells). This reflects a realistic understanding of tissue heterogeneity.<br>   - The analysis also flags non-B-cell markers (e.g., MYL2, BMP6) as likely noise or rare contaminants, avoiding overinterpretation.<br><br>### **Weaknesses (Minor):**<br>1. **Optional Verification**:<br>   - The suggestion to check for **CD138 (SDC1)** and **CD38** is reasonable, but their absence in the marker list does not weaken the annotation. However, explicitly stating that these are not required for validation (given the strong IgA signature) would further solidify confidence.<br><br>2. **Minor Population Clarity**:<br>   - The evidence for a **memory B-cell subset** is weak (only FCRL5, LILRB4). While plausible, it might be overstating the case to list it as a "subtype" rather than a "potential minor contaminant."<br><br>### **Overall Assessment**:<br>The annotation is exceptionally well-justified, with no major oversights or misclassifications. It balances marker importance, aligns with known biology, and provides a clear, comprehensive view of the cell population. The minor weaknesses do not detract from the overall quality.<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    